Figure 5From: ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedsideEfficacy of ABT-869 in combination with carboplatin-paclitaxel in a NSCLC xenograft. ABT-869 was administered orally at the indicated dose for 3 weeks and carboplatin-paclitaxel was administered weekly (IP and IV respectively) beginning 3 weeks after inoculation of H1299 cells into the flank of SCID/beige mice. Percent inhibition of tumor size relative to vehicle treated control was calculated at the end of the study is indicated in parentheses in the legend.Back to article page